AI in 3D compound design.

The success of Artificial Intelligence (AI) across a wide range of domains has fuelled significant interest in its application to designing novel compounds and screening compounds against a specific target. However, many existing AI methods either do not account for the 3D structure of the target at all or struggle to capture meaningful spatial information from the target. In this Opinion, we highlight a range of recent structure-aware approaches which utilise deep learning for compound design and virtual screening. We discuss how such methods can be better integrated into existing drug discovery pipelines by facilitating the design of compounds which conform to a specified design hypothesis and by uncovering key protein-ligand interactions which can be used to aid molecule design.